FDA OK for CMS' Atlas-based Autosegmentation
This article was originally published in Clinica
The US FDA has granted 510(k) clearance for CMS' Atlas-based Autosegmentation (ABAS) software, which produces estimates of anatomy boundary contours to create a radiotherapy treatment plan. The St Louis, Missouri-based company, a subsidiary of Stockholm, Sweden-based Elekta, filed the product in April. The software helps clinicians save time, CMS says, as contouring is usually a time-consuming process. ABAS is also compatible with any radiation treatment planning system that can read standard DICOM RT structure set files, distinguishing it from competing products, the firm added. It has structure-specific algorithms for head and neck and prostate cancer treatments, as well as a general algorithm for other sites.